Fundraising FoxSun BioPharma
Waconia, US · Delaware corporation
Find your way into Sun BioPharma
Sign up to see every warm intro you have to Sun BioPharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Sun BioPharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
SK
SCOTT KELLENExecutive
DB
DAVID B. KAYSENExecutive
MT
MICHAEL T. CULLENNamed on SEC filing
Board
DS
DALVIR S. GILLBoard director
SG
SUZANNE GAGNONBoard director
JR
J. ROBERT PAULSONBoard director
DR
D. ROBERT SCHEMELBoard director
JS
JEFFREY S. MATHIESENBoard director
PW
PAUL W. SCHAFFERBoard director
Reported raises · per SEC filings
Form D private placements$22.3M disclosed across 8 rounds · 2016–2023
▶$2MraisedJan 2024 · 2 investors · PharmaceuticalsRule 506(b)
▶$2MraisedJan 2024 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jennifer K. SimpsonExecutive Officer, Director
- Daniel DonovanDirector
- Jeffrey S. MathiesenDirector
- Susan HorvathExecutive Officer
- Arthur J. FratamicoDirector
- Jeffrey E. JacobDirector
- Michael T. CullenDirector
- Robert SchemelDirector
- Amount sold
- $2M
- Sales commissions
- $120K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedNov 2023 · 3 investors · PharmaceuticalsRule 506(b)
▶$3.3MraisedNov 2023 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Daniel DonovanDirector
- Robert SchemelDirector
- Michael T. CullenDirector
- Jeffrey E. JacobDirector
- Susan HorvathExecutive Officer
- Jeffrey S. MathiesenDirector
- Arthur J. FratamicoDirector
- Jennifer K. SimpsonExecutive Officer, Director
- Amount sold
- $3.3M
- Sales commissions
- $114K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.8MraisedJun 2022 · 70 investors · PharmaceuticalsRule 506(b)
▶$8.8MraisedJun 2022 · 70 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jennifer K. SimpsonExecutive Officer, Director
- Michael T. CullenDirector
- Jeffrey S. MathiesenDirector
- Daniel DonovanDirector
- Robert D. SchemelDirector
- Susan HorvathExecutive Officer
- Jeffrey E. JacobDirector
- Arthur J. FratamicoDirector
- Amount sold
- $8.8M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedSep 2019 · 38 investors · PharmaceuticalsRule 506(b)
▶$2.5MraisedSep 2019 · 38 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Paul W. SchafferDirector
- Robert D. SchemelDirector
- Susan M. HorvathExecutive Officer
- Michael T. CullenExecutive Officer, Director
- Jeffrey S. MathiesenDirector
- Suzanne GagnonDirector
- Amount sold
- $2.5M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MraisedJan 2019 · 15 investors · PharmaceuticalsRule 506(b)
▶$1.4MraisedJan 2019 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- SUSAN M. HORVATHExecutive Officer
- JEFFREY S. MATHIESENDirector
- PAUL W. SCHAFFERDirector
- MICHAEL T. CULLENExecutive Officer, Director
- SUZANNE GAGNONDirector
- D. ROBERT SCHEMELDirector
- J. ROBERT PAULSON, JR.Director
- Offering amount
- $2M
- Amount sold
- $1.4M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$840KraisedMar 2018 · 13 investors · PharmaceuticalsRule 506(b)
▶$840KraisedMar 2018 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- MICHAEL T. CULLENExecutive Officer, Director
- DAVID B. KAYSENExecutive Officer, Director
- SUZANNE GAGNONDirector
- D. ROBERT SCHEMELDirector
- PAUL W. SCHAFFERDirector
- J. ROBERT PAULSON, JR.Director
- SCOTT KELLENExecutive Officer
- JEFFREY S. MATHIESENDirector
- DALVIR S. GILLDirector
- Offering amount
- $20M
- Amount sold
- $840K
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedMar 2017 · 14 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedMar 2017 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Suzanne GagnonDirector
- Paul W SchafferDirector
- David B KaysenExecutive Officer, Director
- D. Robert SchemelDirector
- Scott KellenExecutive Officer
- Jeffrey S MathiesenDirector
- Michael T CullenExecutive Officer, Director
- J. Robert Paulson, Jr.Director
- Dalvir S GillDirector
- Offering amount
- $5M
- Amount sold
- $1.5M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedJun 2016 · 27 investors · PharmaceuticalsRule 506(b)
▶$2MraisedJun 2016 · 27 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- DALVIR S. GILLDirector
- SUZANNE GAGNONDirector
- J. ROBERT PAULSONDirector
- D. ROBERT SCHEMELDirector
- MICHAEL T. CULLENExecutive Officer, Director
- JEFFREY S. MATHIESENDirector
- PAUL W. SCHAFFERDirector
- SCOTT KELLENExecutive Officer
- DAVID B. KAYSENExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $2M
- Finders' fees
- $75K
- Placement agents
- LAKE STREET CAPITAL MARKETS, LLC, CHARDAN CAPITAL MARKETS LLC
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Sun BioPharma raised?
- Sun BioPharma has disclosed $22.3M raised across 8 rounds.
- Where is Sun BioPharma headquartered?
- Sun BioPharma is headquartered in Waconia, US.